Business
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injectionsJERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides and proteins replacement therapies, today announced new validating in vivo pharmacokinetic and pharmacodynamic data that supports further development of a proprietary long-acting par
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio","displaySize":"","headline":null,"caption":"Entera Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":237,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/a305198754d6a07fdaecab02b3a9d515"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PKeefwE624EAwJoXBY3bXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a305198754d6a07fdaecab02b3a9d515","width":237,"height":138}},"lazy":false},{"type":"text","content":"Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections","length":171,"tagName":"p"},{"type":"text","content":"JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides and proteins replacement therapies, today announced new validating in vivo pharmacokinetic and pharmacodynamic data that supports further development of a proprietary long-acting parathyroid hormone (PTH) analog using its N-Tab® platform to create the first once-daily tablet treatment for patients with hypoparathyroidism (EB612 program). The positive preclinical findings showed the proprietary analog achieved a markedly longer plasma half-life and sustained calcium elevation for over three days - in contrast to unmodified PTH(1-34) controls, which showed no calcium response.","length":737,"tagName":"p"},{"type":"text","content":"Hypoparathyroidism is a heterogeneous, rare endocrine disorder characterized by deficient PTH production, hypocalcemia, and hyperphosphatemia. Historically, the standard of care included high dose calcium and calcitriol supplementation. However, raising serum calcium to normal physiological levels in the absence of PTH frequently leads to elevated urinary calcium and is often associated with ectopic calcification, including nephrocalcinosis and renal failure. Today, the only approved PTH replacement treatment (YORVIPATH®) requires patients to administer injections every day, while investigational candidates may require patients to take weekly injections. ","length":663,"tagName":"p"},{"type":"text","content":"Entera previously demonstrated proof of concept data for its EB612 program using an unmodified PTH(1-34) analog and an ...